查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1684286

失眠治疗市场，按治疗类型、按药物类别、按给药途径、按配销通路、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Insomnia Therapeutics Market, By Therapeutics Type, By Drug Class, By Route of Administration, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

失眠治疗市场规模在 2024 年价值 29.0232 亿美元，2025 年至 2032 年期间的复合年增长率为 4.90%。

失眠治疗市场-市场动态

精神健康障碍增加推动失眠治疗需求

精神健康障碍的增加极大地推动了对失眠治疗的需求，因为焦虑、忧郁和压力相关疾病等情况会导致睡眠障碍。根据世界卫生组织 (WHO) 的数据，忧郁症影响全球超过 2.8 亿人，睡眠问题是其常见症状。美国国家心理健康研究所（NIMH）强调，患有焦虑症的人罹患慢性失眠症的风险更高。这导致失眠认知行为疗法（CBT-I）被越来越多地采用作为一线治疗方法，同时药理学解决方案也取得了进展，例如双重食慾素受体拮抗剂，与传统镇静剂相比，其安全性更高。此外，FDA 批准的 Somryst 等数位疗法正在被纳入心理健康护理计划，提供可及的非药物治疗选择。人们越来越认识到心理健康和睡眠障碍之间的联繫，这促使医疗保健提供者和製药公司开发更有效和个人化的失眠疗法。

失眠治疗市场-关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年），全球市场预计年复合成长率约为 4.90%

根据治疗类型细分，非苯二氮平类药物预计将在 2024 年占据最大市场份额

根据药物类别细分，非苯二氮平类催眠药是 2024 年领先的药物类别

根据给药途径细分，口服是 2024 年领先的给药途径

从地区来看，北美是 2024 年最大的收入来源

失眠治疗市场-細項分析：

全球失眠治疗市场根据治疗类型、药物类别、给药途径、配销通路和地区进行细分。

根据治疗类型，市场分为五类：苯二氮平类药物、非苯二氮平类药物、抗忧郁剂、食慾素拮抗剂、褪黑激素拮抗剂和其他。非苯二氮平类药物因其有效性和较低的依赖风险而占据市场主导地位。随后，食慾素拮抗剂作为更安全的替代品逐渐受到关注。抗忧郁药物被广泛用于治疗合併失眠症，而苯二氮平类药物儘管有依赖性问题但仍在使用。褪黑激素拮抗剂和其他疗法可满足特定患者的需求。

依药物类别，市场分为六类：苯二氮平类药物、非苯二氮平催眠药、褪黑激素受体激动剂、食慾素受体拮抗剂、抗忧郁剂。非苯二氮平类催眠药物因其疗效和降低的依赖风险而占据主导地位。作为更安全的替代品，食慾素受体拮抗剂正在迅速占领市场。抗忧郁药物广泛用于治疗与精神健康状况相关的失眠症，而苯二氮平类药物和褪黑激素受体激动剂则服务于小众患者群体。

失眠治疗市场-地理洞察

由于失眠盛行率高、精神健康障碍增加以及医疗保健基础设施强大，北美在失眠治疗市场占据主导地位。在美国，失眠认知行为疗法（CBT-I）和处方药被广泛采用，FDA 批准了像 daridorexant 这样的新一代睡眠辅助药物。欧洲紧随其后，随着人们对睡眠障碍的认识不断提高，以及政府支持的心理健康计划推动了对先进疗法的需求。德国、英国和法国等国家正经历数位治疗的激增，并整合了人工智慧睡眠监测解决方案。在亚太地区，生活方式的改变、工作压力以及城市化导致失眠负担加重，尤其是在中国、日本和印度。这些国家中草药和替代性睡眠疗法的使用日益增多，也呈现出独特的市场趋势。同时，拉丁美洲和中东及非洲是新兴市场，这些地区的医疗保健服务日益普及，宣传活动不断加强，推动人们逐步采用药物和非药物治疗失眠的方法。

失眠治疗市场-竞争格局：

失眠治疗市场竞争激烈，製药巨头、数位健康公司和新兴生技公司都专注于创新治疗方案。默克公司、卫材公司和 Idorsia Pharmaceuticals 等领先公司正在推进下一代失眠药物，包括双食慾素受体拮抗剂，如 suvorexant 和 daridorexant，与传统镇静剂相比，它们的安全性更高。同时，Jazz Pharmaceuticals 和辉瑞等公司继续扩大其睡眠障碍药物组合。数位治疗领域也正在获得关注，FDA 批准的解决方案，如 Pear Therapeutics 的 Somryst，透过失眠认知行为疗法 (CBT-I) 提供非药物替代方案。新创公司和科技公司正在开发人工智慧驱动的睡眠监测设备和穿戴式技术，以个人化治疗方法。儘管市场取得了进步，但药物依赖性问题、监管障碍以及草药等替代疗法的竞争等挑战仍然影响着市场动态。策略合作、产品创新和扩大分销网络仍然是旨在加强失眠治疗市场地位的公司的关键策略。

最新动态：

2020 年 7 月，卫材在日本推出了 DAYVIGO(R)（lemborexant），用于治疗失眠。这种双重食慾素受体拮抗剂有助于睡眠的开始和维持。批准是基于第三阶段试验的结果，该试验表明，与安慰剂和唑吡坦相比，该药物可以改善睡眠，主要副作用是嗜睡、头痛和头晕。

2024 年 12 月，Shionogi 和 Nxera Pharma 在日本推出 QUVIVIQ(TM)（daridorexant），作为治疗成人失眠的新药物。这种口服药物可以选择性地阻断食慾素受体，透过抑制过度清醒来促进睡眠。盐野义将负责分销和销售。

目录

第 1 章：失眠治疗市场概述

  • 研究范围
  • 市场估计年限

第 2 章：执行摘要

  • 市场片段
    • 失眠治疗市场片段（按治疗类型）
    • 失眠治疗药物市场片段（依药物类别）
    • 失眠治疗市场片段（依给药途径）
    • 失眠治疗市场片段（按配销通路）
    • 失眠治疗市场片段（按国家/地区）
    • 失眠治疗市场片段（按地区）
  • 竞争洞察

第 3 章：失眠治疗关键市场趋势

  • 失眠治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 失眠治疗市场限制
    • 市场限制的影响分析
  • 失眠治疗市场机会
  • 失眠治疗市场未来趋势

第 4 章：失眠治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景规划
  • 规范架构分析

第 5 章：失眠治疗市场：地缘政治紧张局势升级的影响

  • 新冠肺炎疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第 6 章：失眠治疗市场格局

  • 失眠治疗市占率分析，2024 年
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第 7 章：失眠治疗市场 - 依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 苯二氮平类
    • 非苯二氮平类
    • 抗忧郁药
    • 食慾素拮抗剂
    • 褪黑素拮抗剂
    • 其他的

第 8 章：失眠治疗市场 - 依药物类别

  • 概述
    • 按药物类别进行细分份额分析
    • 苯二氮平类
    • 非苯二氮平类催眠药
    • 褪黑激素受体激动剂
    • 食慾素受体拮抗剂
    • 抗忧郁药

第 9 章：失眠治疗市场 - 按给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 舌下
    • 静脉
    • 透皮
    • 鼻腔

第 10 章：失眠治疗市场 - 按配销通路

  • 概述
    • 按配销通路进行细分市场份额分析
    • 医院药房
    • 零售药局
    • 网路药局
    • 诊所
    • 健康中心

第 11 章：失眠治疗市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美失眠治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按治疗类型）
    • 北美市场规模及预测（依药品类别）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模及预测（按配销通路划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲失眠治疗主要製造商
    • 欧洲市场规模及预测（按国家）
    • 欧洲市场规模及预测（按治疗类型）
    • 欧洲市场规模及预测（依药品类别）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（依配销通路划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区失眠治疗主要製造商
    • 亚太地区市场规模及预测（依国家/地区划分）
    • 亚太地区市场规模及预测（依治疗类型）
    • 亚太地区市场规模及预测（依药品类别）
    • 亚太地区市场规模及预测（依管理途径划分）
    • 亚太地区市场规模及预测（依配销通路划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲 (LATAM)
    • 概述
    • 拉丁美洲失眠治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按治疗类型）
    • 拉丁美洲市场规模及预测（依药品类别）
    • 拉丁美洲市场规模及预测（依管理途径划分）
    • 拉丁美洲市场规模及预测（按配销通路划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲 (MEA)
    • 概述
    • 中东和非洲失眠治疗主要製造商
    • MEA 市场规模及预测（依国家/地区划分）
    • MEA 市场规模及预测（依治疗类型）
    • MEA 市场规模及预测（依药物类别）
    • MEA 市场规模及预测（依给药途径）
    • MEA 市场规模及预测（依配销通路划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其他地区

第 12 章：失眠治疗产业主要供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Astellas Pharma Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Eisai Co., Ltd.
    • Lupin Limited
    • Merck & Co., Inc.
    • Mylan NV
    • Paratek Pharmaceuticals, Inc.
    • Pernix Therapeutics Holdings, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Sumitomo Dainippon Pharma Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • Torrent Pharmaceuticals Ltd.
    • Vanda Pharmaceuticals Inc.
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4883

REPORT HIGHLIGHT

Insomnia Therapeutics Market size was valued at US$ 2,902.32 Million in 2024, expanding at a CAGR of 4.90% from 2025 to 2032.

The insomnia therapeutics market focuses on treatments designed to manage and alleviate sleep disorders, particularly chronic and acute insomnia. Rising stress levels, increasing cases of mental health disorders, and lifestyle changes have significantly contributed to the growing prevalence of insomnia, with the CDC reporting that one in three adults in the U.S. does not get enough sleep. Pharmaceutical advancements, including orexin receptor antagonists like lemborexant and daridorexant, are enhancing treatment efficacy while reducing dependency risks associated with traditional benzodiazepines. Additionally, the expansion of cognitive behavioral therapy for insomnia (CBT-I) as a preferred non-pharmacological intervention is gaining traction, with digital therapeutics platforms like Somryst receiving FDA approval. However, side effects related to sedative-hypnotic drugs and the risk of dependency pose challenges to market growth. Opportunities lie in integrating AI-powered sleep monitoring devices and wearable technology, which provide personalized therapy insights. As awareness of sleep health increases, the demand for innovative and safer insomnia treatments continues to grow.

Insomnia Therapeutics Market- Market Dynamics

Rising Mental Health Disorders Driving Demand for Insomnia Therapeutics

Rising mental health disorders are significantly driving demand for insomnia therapeutics, as conditions like anxiety, depression, and stress-related disorders contribute to sleep disturbances. According to the World Health Organization (WHO), depression affects over 280 million people worldwide, with sleep issues being a common symptom. The National Institute of Mental Health (NIMH) highlights that individuals with anxiety disorders are at a higher risk of developing chronic insomnia. This has led to increased adoption of cognitive behavioral therapy for insomnia (CBT-I) as a first-line treatment, alongside advancements in pharmacological solutions such as dual orexin receptor antagonists, which offer improved safety profiles compared to traditional sedatives. Additionally, digital therapeutics like FDA-approved Somryst are being integrated into mental health care plans, providing accessible, non-drug treatment options. The growing recognition of the link between mental health and sleep disorders is pushing healthcare providers and pharmaceutical companies to develop more effective and personalized insomnia therapies.

Insomnia Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2025-2032)

Based on Therapeutics Type segmentation, Nonbenzodiazepines was predicted to show maximum market share in the year 2024

Based on Drug Class segmentation, non-benzodiazepine hypnotics was the leading Drug Class in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

On the basis of region, North America was the leading revenue generator in 2024

Insomnia Therapeutics Market- Segmentation Analysis:

The Global Insomnia Therapeutics Market is segmented on the basis of Therapeutics Type, Drug Class, Route of Administration, Distribution Channel, and Region.

The market is divided into five categories based on Therapeutics Type: Benzodiazepines, Nonbenzodiazepines, Antidepressants, Orexin Antagonists, Melatonin Antagonists, and Others. Nonbenzodiazepines lead the market due to their effectiveness and lower dependency risk. Orexin antagonists follow, gaining traction as safer alternatives. Antidepressants are widely prescribed for comorbid insomnia, while benzodiazepines remain in use despite dependency concerns. Melatonin antagonists and other therapies cater to specific patient needs.

The market is divided into six categories based on Drug Class: Benzodiazepines, Non-Benzodiazepine Hypnotics, Melatonin Receptor Agonists, Orexin Receptor Antagonists, and Antidepressants. Non-benzodiazepine hypnotics dominate due to their efficacy and reduced dependency risks. Orexin receptor antagonists are rapidly gaining market share as safer alternatives. Antidepressants are widely used for insomnia linked to mental health conditions, while benzodiazepines and melatonin receptor agonists serve niche patient segments.

Insomnia Therapeutics Market- Geographical Insights

North America dominates the insomnia therapeutics market due to high insomnia prevalence, rising mental health disorders, and strong healthcare infrastructure. The U.S., in particular, sees widespread adoption of cognitive behavioral therapy for insomnia (CBT-I) and prescription medications, with the FDA approving new-generation sleep aids like daridorexant. Europe follows closely, with increasing awareness of sleep disorders and government-backed mental health initiatives driving demand for advanced therapeutics. Countries such as Germany, the UK, and France are witnessing a surge in digital therapeutics, integrating AI-powered sleep monitoring solutions. In the Asia-Pacific region, changing lifestyles, work-related stress, and urbanization contribute to a growing insomnia burden, particularly in China, Japan, and India. The rising use of herbal and alternative sleep remedies in these countries also presents a unique market trend. Meanwhile, Latin America and the Middle East & Africa are emerging markets, where increasing healthcare access and awareness campaigns are driving gradual adoption of pharmaceutical and non-pharmaceutical insomnia treatments.

Insomnia Therapeutics Market- Competitive Landscape:

The insomnia therapeutics market is highly competitive, with pharmaceutical giants, digital health companies, and emerging biotech firms focusing on innovative treatment solutions. Leading players such as Merck & Co., Eisai Co., and Idorsia Pharmaceuticals are advancing next-generation insomnia drugs, including dual orexin receptor antagonists like suvorexant and daridorexant, which offer improved safety profiles over traditional sedatives. Meanwhile, companies like Jazz Pharmaceuticals and Pfizer continue to expand their sleep disorder drug portfolios. The digital therapeutics segment is also gaining traction, with FDA-approved solutions such as Pear Therapeutics' Somryst offering non-drug alternatives through cognitive behavioral therapy for insomnia (CBT-I). Startups and tech firms are developing AI-driven sleep monitoring devices and wearable technology to personalize treatment approaches. Despite market advancements, challenges such as drug dependency concerns, regulatory hurdles, and competition from alternative treatments like herbal remedies impact market dynamics. Strategic collaborations, product innovation, and expanding distribution networks remain key strategies for companies aiming to strengthen their market presence in insomnia therapeutics.

Recent Developments:

In July 2020, Eisai launched DAYVIGO(R) (lemborexant) in Japan, for treating insomnia. This dual orexin receptor antagonist facilitates sleep onset and maintenance. Approval was based on Phase III trials showing improved sleep compared to placebo and zolpidem, with somnolence, headache, and dizziness as main side effects.

In December 2024, Shionogi and Nxera Pharma launched QUVIVIQ(TM) (daridorexant) in Japan as a new treatment for adults with insomnia. This oral medication selectively blocks orexin receptors, promoting sleep by inhibiting excessive wakefulness. Shionogi will handle distribution and sales.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INSOMNIA THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Paratek Pharmaceuticals, Inc.
  • Pernix Therapeutics Holdings, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.
  • Others

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY THERAPEUTICS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Benzodiazepines
  • Nonbenzodiazepines
  • Antidepressants
  • Orexin Antagonists
  • Melatonin Antagonists
  • Others

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Benzodiazepines
  • Non-Benzodiazepine Hypnotics
  • Melatonin Receptor Agonists
  • Orexin Receptor Antagonists
  • Antidepressants

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Sublingual
  • Intravenous
  • Transdermal
  • Nasal

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Clinics
  • Wellness Centers

GLOBAL INSOMNIA THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Insomnia Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Insomnia Therapeutics Market Snippet by Therapeutics Type
    • 2.1.2. Insomnia Therapeutics Market Snippet by Drug Class
    • 2.1.3. Insomnia Therapeutics Market Snippet by Route of Administration
    • 2.1.4. Insomnia Therapeutics Market Snippet by Distribution Channel
    • 2.1.5. Insomnia Therapeutics Market Snippet by Country
    • 2.1.6. Insomnia Therapeutics Market Snippet by Region
  • 2.2. Competitive Insights

3. Insomnia Therapeutics Key Market Trends

  • 3.1. Insomnia Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Insomnia Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Insomnia Therapeutics Market Opportunities
  • 3.4. Insomnia Therapeutics Market Future Trends

4. Insomnia Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Insomnia Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Insomnia Therapeutics Market Landscape

  • 6.1. Insomnia Therapeutics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Insomnia Therapeutics Market - By Therapeutics Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapeutics Type, 2024 & 2032 (%)
    • 7.1.2. Benzodiazepines
    • 7.1.3. Nonbenzodiazepines
    • 7.1.4. Antidepressants
    • 7.1.5. Orexin Antagonists
    • 7.1.6. Melatonin Antagonists
    • 7.1.7. Others

8. Insomnia Therapeutics Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 8.1.2. Benzodiazepines
    • 8.1.3. Non-Benzodiazepine Hypnotics
    • 8.1.4. Melatonin Receptor Agonists
    • 8.1.5. Orexin Receptor Antagonists
    • 8.1.6. Antidepressants

9. Insomnia Therapeutics Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Sublingual
    • 9.1.4. Intravenous
    • 9.1.5. Transdermal
    • 9.1.6. Nasal

10. Insomnia Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies
    • 10.1.5. Clinics
    • 10.1.6. Wellness Centers

11. Insomnia Therapeutics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Insomnia Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Insomnia Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Insomnia Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Insomnia Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Insomnia Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Therapeutics Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Insomnia Therapeutics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Astellas Pharma Inc.
    • 12.2.2. Dr. Reddy's Laboratories Ltd.
    • 12.2.3. Eisai Co., Ltd.
    • 12.2.4. Lupin Limited
    • 12.2.5. Merck & Co., Inc.
    • 12.2.6. Mylan N.V.
    • 12.2.7. Paratek Pharmaceuticals, Inc.
    • 12.2.8. Pernix Therapeutics Holdings, Inc.
    • 12.2.9. Pfizer Inc.
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Sumitomo Dainippon Pharma Co., Ltd.
    • 12.2.12. Sun Pharmaceutical Industries Ltd.
    • 12.2.13. Takeda Pharmaceutical Company Limited
    • 12.2.14. Teva Pharmaceutical Industries Ltd.
    • 12.2.15. Torrent Pharmaceuticals Ltd.
    • 12.2.16. Vanda Pharmaceuticals Inc.
    • 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us